Polomar Health Services, Inc. (formerly Trustfeed Corp.) reported a significant decline in financial performance for the third quarter of 2025, with revenues of $6.2 million, down 37% from $9.8 million in the same period last year. For the nine months ending September 30, 2025, total revenue was $16.2 million, a decrease of 57% compared to $38 million for the same period in 2024. The company also reported a net loss of $649,775 for the third quarter, compared to a loss of $271,333 in the prior year, and a cumulative net loss of $1.7 million for the first nine months of 2025, up from $622,544 in 2024.
The company’s operational changes have contributed to these financial results. Polomar Pharmacy, which operates as a retail compounding pharmacy, has shifted its business model from local fulfillment of compounded dermatological medications to a national online fulfillment model for GLP-1 agonists and erectile dysfunction drugs. This transition has resulted in a decline in revenues due to delays in product development and supply chain issues. The company has also faced increased labor costs, which have further impacted profitability. As of September 30, 2025, Polomar Pharmacy is licensed to fulfill prescriptions in 30 states and is actively seeking to expand its reach.
In terms of operational metrics, Polomar Health Services has seen a notable increase in its employee headcount, which rose to 28,019,624 shares outstanding as of September 30, 2025, compared to 27,657,679 shares at the end of 2024. The company has also entered into strategic agreements, including a one-year pharmacy services agreement with CareValidate, Inc., to fulfill GLP-1 agonist prescriptions, which is expected to drive revenue growth. Additionally, Polomar is planning to launch SlimRx, an online platform for weight loss medications, in early 2026, and PoloMeds, which will focus on diabetes medications, in the first quarter of 2026.
Looking ahead, Polomar Health Services anticipates steady revenue growth from its new customer agreements and the expansion of its product offerings. The company is focused on overcoming the challenges associated with its transition to a national fulfillment model and is actively working to resolve supply chain issues. Management remains optimistic about the potential for growth in the telehealth market and the fulfillment of prescriptions through third-party platforms, which they believe will enhance the company’s market position in the coming months.
About Polomar Health Services, Inc.
Polomar Health Services Inc. operates a licensed specialty pharmacy specializing in sterile and compounded medications across multiple states. It offers prescription fulfillment, including weight loss, diabetes, and dermatological products, often via telehealth partnerships. The company leverages licensed intellectual property and proprietary formulations, focusing on innovative pharmaceutical delivery. Its business model centers on healthcare services, prescription compounding, and online platforms serving diverse patient needs.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.